Trending Topics in Gastroenterology | GastroAGI

Histone H4 Dopaminylation Emerges as a Novel Epigenetic Regulator of Tumor Growth : Nat Chem Biol | May 2026

Introduction Post-translational modifications are fundamental regulators of gene expression, chromatin organization and cellular behavior. Dopaminylation, a recently identified modification involving covalent attachment of dopamine to glutamine residues on proteins, has emerged as a novel signaling mechanism, although its biologic functions and substrate landscape remain poorly understood. Problem Statement The absence of robust methods to comprehensively identify dopaminylated proteins has limited understanding of how dopamine-mediated protein modification influences transcriptional regulation and cancer biology. Whether dopaminylation participates directly in epigenetic control mechanisms and tumor growth regulation has remained largely unknown. Summary This study introduces a chemoproteomic platform capable of systematically identifying dopaminylated proteins and substantially expands the known dopaminylation landscape. Using an alkyne-functionalized dopamine probe, the investigators identified more than a thousand putative dopaminylated proteins and characterized histone H4 dopaminylation at glutamine 27 as a previously unrecognized epigenetic modification. Functional analyses demonstrated that H4Q27 dopaminylation acts as a transcriptional repressor in neuroblastoma cells by inhibiting binding of the transcription factor CEBPD at the CCND1 promoter, leading to cyclin D1 suppression and reduced cellular proliferation. These findings establish a direct mechanistic link between dopamine-associated protein modification and chromatin-mediated control of tumor growth. Importantly, the work extends the biologic significance of dopamine beyond neurotransmission and suggests that dopaminylation may represent a broader regulatory system influencing transcriptional programs, cell-cycle progression and oncogenesis. The large-scale substrate dataset generated in this study also provides a major resource for future exploration of dopamine-mediated signaling across multiple physiologic and disease contexts. Overall, this research identifies dopaminylation as an emerging epigenetic mechanism with potential implications for cancer biology and future therapeutic targeting.

Two Decades of PARP Inhibitor Synthetic Lethality Redefined Precision Oncology : Nature | May 2026

Introduction The discovery of synthetic lethality between BRCA1/BRCA2 deficiency and PARP inhibition fundamentally transformed cancer therapeutics and became one of the defining advances in modern precision oncology. By selectively targeting DNA repair vulnerabilities in tumor cells, PARP inhibitors established a new paradigm in which inherited or acquired genomic defects could guide highly personalized cancer treatment. Problem Statement Before the development of PARP inhibitors, targeted cancer therapies largely focused on directly inhibiting activated oncogenic drivers. However, many tumor suppressor gene alterations, including BRCA1 and BRCA2 loss, were considered therapeutically “undruggable.” A major challenge was determining whether vulnerabilities created by defective DNA repair pathways could be exploited therapeutically without excessive toxicity to normal tissues. Summary This perspective reviews the scientific and clinical evolution of PARP inhibitor synthetic lethality over the past two decades and highlights its transformative impact on oncology. The original observation that PARP inhibition selectively kills BRCA-deficient cells established the first successful therapeutic strategy directly linked to a germline biomarker and fundamentally changed treatment approaches in breast, ovarian, prostate and pancreatic cancers. Beyond improving survival, PARP inhibitors also demonstrated that targeting DNA repair dependency could achieve meaningful efficacy with comparatively favorable tolerability. Importantly, the clinical success of PARP inhibitors extended the role of BRCA testing from hereditary cancer risk assessment to routine therapeutic decision-making, embedding germline genetics into mainstream oncology practice. The article also emphasizes the broader biologic significance of synthetic lethality, showing how functional redundancies within tumor cells create exploitable therapeutic dependencies. This concept has since driven extensive efforts to identify additional synthetic lethal interactions across cancer biology. At the same time, the review acknowledges ongoing challenges, including resistance mechanisms, incomplete biomarker precision and variability in response beyond canonical BRCA-mutated tumors. Overall, the PARP inhibitor story represents a landmark example of translational medicine in which fundamental biologic discovery directly reshaped cancer care and established synthetic lethality as a central framework for future targeted therapy development.

Repurposing Legacy Cytotoxics May Define the Next Generation of ADCs : Trends in Cancer | May 2026

Introduction Antibody–drug conjugates (ADCs) have transformed oncology by enabling selective delivery of potent cytotoxic agents directly to tumor cells. Recent successes, particularly with trastuzumab deruxtecan, have expanded the role of ADCs across multiple solid tumors and validated the concept of targeted payload delivery as a major therapeutic platform. Problem Statement Despite rapid clinical expansion, most ADC development programs increasingly rely on a narrow group of payload classes—primarily topoisomerase I inhibitors and microtubule toxins. This mechanistic convergence raises concerns regarding overlapping toxicities, emerging cross-resistance and limited innovation in payload diversity. At the same time, many historically abandoned cytotoxic agents may have failed not because of inadequate antitumor activity, but because systemic exposure rendered them intolerable as free drugs. Summary This perspective proposes a major conceptual shift in ADC development by advocating systematic repurposing of legacy cytotoxic compounds as next-generation ADC payloads. Using trastuzumab deruxtecan as the central model, the authors argue that ADC success depends less on maximal intrinsic potency and more on pharmacologic compatibility with targeted delivery. They introduce a five-pillar framework for payload selection emphasizing proliferation-restricted cytotoxicity, pharmacokinetic “softness,” sustained intracellular target engagement and controlled bystander effects rather than ultrapotent lethality alone. The review highlights multiple underexplored payload classes—including antifolates, nucleoside analogs, kinesin spindle protein inhibitors, noncamptothecin topoisomerase inhibitors and DNA intercalators—that may become clinically viable when delivered through antibody-directed platforms. Importantly, many of these compounds already possess substantial historical pharmacology and toxicity data, potentially accelerating translational development. The authors also emphasize that future ADC innovation will require broader mechanistic diversification to avoid class-wide resistance and toxicity saturation associated with current TOP1-dominant strategies. Overall, this article reframes ADC payload discovery from a potency-driven paradigm toward a systems-level pharmacologic design strategy focused on tumor-selective exposure and biologic precision.

Cytotoxic Tissue-Resident NK Cells Show Potent Antitumor Activity in Solid Tumors : Science Translational Medicine | May 2026

Introduction Natural killer (NK) cell–based immunotherapy has emerged as a promising strategy in cancer treatment because of its ability to mediate tumor killing without prior antigen sensitization. However, clinical efficacy in solid tumors has remained limited, largely due to poor tumor infiltration, immune suppression within the tumor microenvironment and uncertainty regarding the most therapeutically effective NK-cell subsets. Problem Statement Conventional ex vivo expanded NK cells often fail to adequately infiltrate and persist within solid epithelial tumors, reducing their therapeutic effectiveness. At the same time, tissue-resident NK (trNK) cells represent a biologically diverse population, with some subsets demonstrating immunosuppressive properties while others appear highly cytotoxic. Identifying and selectively expanding the most effective antitumor trNK population remains a major challenge in adoptive NK-cell therapy. Summary This translational study identifies a distinct population of highly cytotoxic tissue-resident NK cells characterized by coexpression of CD39, CD49a and CD103, termed cytotoxic trNK (ctrNK) cells, with potent activity against solid epithelial tumors. Using multiomic characterization, the investigators demonstrated that these ctrNK cells possess enhanced tumor-killing capacity, superior migration into tumor organoids and markedly improved control of solid tumors in vivo compared with conventionally activated peripheral NK cells. Importantly, the enhanced antitumor activity appeared linked not only to cytolytic function but also to improved tissue infiltration and retention within the tumor microenvironment, partly mediated through CD103-associated epithelial adhesion mechanisms. A particularly significant finding was that exposure to epithelial tumor cells during ex vivo expansion could drive differentiation toward this highly cytotoxic tissue-resident phenotype, creating a potentially scalable platform for adoptive immunotherapy. These findings directly address one of the major barriers in solid tumor immunotherapy—the inability of transferred immune cells to effectively penetrate and function within immunosuppressive tumor environments. The study positions ctrNK cells as a promising next-generation cellular therapy platform for solid malignancies and provides an important biologic framework for refining NK-cell engineering and expansion strategies in cancer immunotherapy.

Centenarians and the Secret of a Youthful Immune System: Nat Rev Immun | May 2026

Introduction Ageing is typically associated with declining immune function (immunosenescence) and chronic low-grade inflammation (inflammageing), leading to increased susceptibility to infections, cancer, and metabolic diseases. However, centenarians—individuals aged 100 years or more—represent a unique population that defies this paradigm by maintaining relatively preserved immune function and delaying major age-related diseases. Problem Statement The key question is: Why do centenarians escape the typical trajectory of immune decline seen in ageing? Understanding the mechanisms behind their preserved immunity could unlock strategies to improve healthspan and prevent age-related diseases in the general population. Summary This review highlights that centenarians maintain a balanced and resilient immune system across both innate and adaptive compartments. Unlike typical ageing, they demonstrate reduced chronic inflammation, partly due to lower activation of inflammatory pathways such as the NLRP3 inflammasome and a more controlled senescence-associated secretory phenotype. Protective mechanisms include enhanced autophagy, which helps clear damaged cellular components, and preservation of immune cell function resembling that of younger individuals. Omics studies reveal youth-like gene expression patterns, favourable epigenetic profiles, and beneficial gut microbiome composition, all contributing to immune stability. Interestingly, semi-supercentenarians and supercentenarians show even stronger preservation of these features, suggesting that successful ageing involves active biological adaptation rather than passive decline. Overall, centenarians achieve longevity through immune homeostasis, reduced inflammageing, and coordinated molecular adaptations, offering a potential blueprint for therapies aimed at extending healthy lifespan.

TAK1 Blockade May Turn “Cold” Pancreatic Cancer Immunologically Hot: Gastroenterology | May 2026

Introduction and Summary Pancreatic ductal adenocarcinoma remains one of the most immunotherapy-resistant gastrointestinal cancers. A major reason is its dense, immunologically “cold” tumour microenvironment, where cytotoxic T cells are either absent, excluded, or functionally impaired. Despite strong biological rationale, attempts to target the TGF-β pathway to reverse this immune suppression have not yet translated into meaningful clinical success. This study identifies TGF-β-activated kinase 1, also known as TAK1 or MAP3K7, as a key tumour-intrinsic driver of immune resistance in pancreatic cancer. The authors show that TAK1 is aberrantly activated in pancreatic cancer cells and is linked to poor T-cell activity within the tumour microenvironment. Using human pancreatic cancer samples, tumour–T–cell co-culture systems, genetically engineered mouse models, single-cell RNA sequencing, flow cytometry, multiplex immunohistochemistry, proteomics, and mechanistic assays, the study demonstrates that blocking TAK1 induces DNA damage within tumour cells, causes cytoplasmic DNA leakage, and activates the cGAS–STING innate immune pathway. This creates a more inflammatory tumour environment, promotes effector T-cell infiltration, and makes pancreatic tumours more responsive to immune checkpoint blockade. Problem Statement Immune checkpoint inhibitors have transformed several solid tumours, but they have had limited benefit in pancreatic ductal adenocarcinoma. The central challenge is not simply the absence of immune therapy, but the inability of pancreatic tumors to generate a sufficiently inflamed, T-cell-rich microenvironment. TGF-β pathway inhibition has been explored as a strategy to reverse immune suppression, but clinical results have been disappointing. Therefore, there is a need to identify more precise, tumor-specific nodes within this pathway that can convert pancreatic cancer from an immune-resistant tumor into one that is vulnerable to immunotherapy. This study proposes TAK1 as one such target. Key Findings for Clinicians The study shows that TAK1 is activated within pancreatic cancer cells and appears to contribute to T-cell dysfunction in the tumor microenvironment. When TAK1 was inhibited pharmacologically using Takinib, or genetically deleted in pancreatic cancer mouse models, tumors showed increased infiltration of CD4+ and CD8+ effector T cells. Importantly, TAK1 blockade made pancreatic tumors more sensitive to immune checkpoint blockade, suggesting that TAK1 inhibition may act as an immune-sensitizing strategy rather than a simple cytotoxic approach. Mechanistically, TAK1 inhibition caused DNA damage in cancer cells. Damaged DNA leaked into the cytoplasm, where it activated the cGAS–STING pathway, a key innate immune sensing mechanism that promotes inflammatory signaling and adaptive immune recruitment. The study also identifies a molecular repair axis involving TAK1, EphA2, and RAD51. TAK1 phosphorylates EphA2 at serine 897, which then contributes to phosphorylation of RAD51 at tyrosine 315. RAD51 is a major DNA repair protein involved in homologous recombination. In simple terms, TAK1 helps pancreatic cancer cells preserve genomic integrity and avoid immune activation. By blocking TAK1, the tumor cell loses part of its DNA repair protection, accumulates DNA damage, activates innate immune sensing, and becomes more visible to the immune system. Clinical Relevance This is a highly relevant translational study because it addresses one of the most important barriers in pancreatic cancer treatment: resistance to immunotherapy. The findings suggest that pancreatic cancer immune resistance may be partly maintained by tumor-intrinsic TAK1 activity. Rather than only targeting the surrounding stroma or immune cells, this approach targets the cancer cell itself and forces it to generate an inflammatory danger signal through DNA damage and cGAS–STING activation. For clinicians, the most important message is that TAK1 inhibition may potentially convert pancreatic cancer from an immune-cold to an immune-inflamed phenotype, thereby creating a biological rationale for combining TAK1 blockade with immune checkpoint inhibitors. This could be especially relevant in future therapeutic strategies where TAK1 activity, EphA2 signaling, RAD51-mediated DNA repair, or cGAS–STING activation may serve as biomarkers for patient selection. Limitations and Caution This is not yet a clinical practice-changing study. The work is primarily basic and translational, supported by human tissue analysis, in vitro experiments, and genetically engineered mouse models. The therapeutic effect of TAK1 inhibition in human pancreatic cancer patients remains unproven. The safety, dosing, toxicity profile, and therapeutic window of TAK1 inhibitors will require careful evaluation, particularly because TAK1 has important biological functions in inflammatory and survival pathways. It is also unclear whether all pancreatic cancers will respond similarly. PDAC is molecularly and immunologically heterogeneous, and only selected tumors may be vulnerable to TAK1-directed immune sensitization. Finally, activation of cGAS–STING biology can be context-dependent. While it may promote anti-tumor immunity, excessive or chronic pathway activation may have complex effects that need further study. Conclusion This study identifies TAK1 as a critical tumor-intrinsic regulator of DNA repair, immune evasion, and checkpoint inhibitor resistance in pancreatic cancer. By inhibiting TAK1, pancreatic cancer cells develop DNA damage, activate the cGAS–STING pathway, recruit effector T cells, and become more responsive to immune checkpoint blockade in preclinical models. The study provides a strong biological rationale for future development of TAK1-targeted combination therapy with immunotherapy in pancreatic ductal adenocarcinoma. However, clinical validation is essential before this approach can be considered for patient care.

Role of Innate Oral Immunity and Salivary Fluid in IBD: CMGH | April 2026

Introduction Inflammatory bowel disease is increasingly understood as a disorder shaped not only by the gut itself, but also by extraintestinal immune and microbial influences. The oral cavity is one such important site because it is closely linked to the gut through swallowed saliva, oral microbes, and immune mediators. While the contribution of oral adaptive immunity and oral dysbiosis to IBD has been explored previously, the role of oral innate immunity, especially salivary fluid and its bioactive components, has remained unclear. This study examined whether saliva influences the oral microbiome, gut microbiome, gut barrier, and the course of colitis. Problem statement The key unanswered question was whether salivary innate immunity protects the gut or worsens intestinal inflammation, and through what mechanism this effect occurs. Summary This study showed that saliva has surprisingly little influence on the oral microbiome, but it has a clear effect on the gut environment and the severity of colitis. Using two mouse models with reduced salivation, the authors found that lack of saliva delayed the early development of DSS-induced colitis, suggesting that some salivary factors may initially worsen inflammation. However, once disease progressed, these mice developed rapid weight loss and higher mortality, indicating that saliva also contains protective components essential for later gut stability and survival. The most important mechanistic insight was that saliva acts mainly through the gut barrier rather than by major reshaping of the microbiome. Mass spectrometry identified two key salivary molecules with opposing roles. Trefoil factor 2 (TFF2) acted as a protective peptide, helping preserve gut barrier integrity and reducing colitis severity. In contrast, macrophage migration inhibitory factor (MIF) acted as a damaging cytokine that worsened inflammation. Neutralizing TFF2 aggravated colitis, whereas neutralizing MIF was protective. Overall, the study proposes that oral innate immunity is an important upstream regulator of gut inflammation. Saliva is not merely a digestive fluid; it carries immunologically active molecules that can either protect or damage the intestine depending on the disease stage. Clinically, this opens an interesting therapeutic concept: reducing salivary MIF or enhancing TFF2 may become a novel strategy for IBD treatment.

Microbiota–Inflammasome Axis: Gut | April 2026

Introduction The gastrointestinal tract functions as a highly integrated system where digestion, immunity, and metabolic regulation are closely linked to the gut microbiota. This vast microbial ecosystem plays a central role in maintaining mucosal integrity, immune balance, and systemic homeostasis. A key emerging regulator in this interaction is the inflammasome, a multiprotein complex that senses microbial and cellular danger signals and orchestrates innate immune responses. The microbiota–inflammasome axis has recently gained attention as a crucial bridge connecting gut health with systemic diseases, including cancer, metabolic disorders, and neurological conditions. Problem Statement Despite growing recognition of the microbiota’s role in disease, the precise mechanisms through which dysbiosis triggers pathological immune activation remain incompletely understood. In particular, the role of inflammasomes as central mediators of microbiota-driven inflammation is underexplored. This gap limits our ability to translate microbiome science into targeted therapies, especially in complex diseases such as inflammatory bowel disease, gastrointestinal cancers, and neuroinflammatory disorders. Summary This review highlights that dysbiosis can aberrantly activate inflammasomes, disrupting gut homeostasis and promoting chronic inflammation. The microbiota–inflammasome axis influences not only gastrointestinal diseases but also systemic conditions via pathways such as the gut–brain axis, including vagal signaling and neuroendocrine responses. Importantly, inflammasome-mediated cytokines act as key messengers linking gut-derived signals to distant organs. Emerging evidence also demonstrates a role in cancer progression and immune modulation. The integration of artificial intelligence is accelerating understanding of these complex interactions, enabling biomarker discovery and therapeutic targeting. Overall, the microbiota–inflammasome axis represents a promising frontier for precision medicine across gastrointestinal and systemic diseases.

Non-invasive Assessment of Gut Barrier Function in Environmental Enteropathy Using TFS: Gut | April 2026

Introduction Undernutrition remains a major global health challenge, particularly in low-resource settings, and is closely linked to a complex gut disorder known as environmental enteropathy (EE). EE is characterised by impaired intestinal barrier function (“leaky gut”), inflammation, and reduced nutrient absorption, which together limit the effectiveness of nutritional interventions. Accurate assessment of intestinal permeability is therefore crucial, but existing methods such as lactulose: rhamnose (LR) testing are cumbersome, invasive, costly, and difficult to implement at scale. Problem Statement Current diagnostic tools for evaluating gut barrier dysfunction in EE lack feasibility for widespread clinical and field use, especially in vulnerable populations like children and those in resource-limited regions. There is an urgent need for a rapid, reliable, non-invasive, and scalable method to assess intestinal permeability and overall gut function. Summary This study introduces transcutaneous fluorescence spectroscopy (TFS), a novel, non-invasive, sample-free technique that measures intestinal permeability through skin-based detection of fluorescent markers. TFS successfully differentiated increased gut permeability in Zambian participants with EE compared to healthy UK controls and showed a strong correlation with the conventional LR test (r≥0.78). Importantly, TFS allows simultaneous assessment of intestinal barrier integrity and gastric emptying without the need for biological sample collection. These findings position TFS as a promising tool for large-scale, real-time monitoring of gut health, particularly in low-resource settings, with potential applications beyond EE, including IBD and coeliac disease.

Dengue Suppression by Male Wolbachia-Infected Mosquitoes: NEJM | March 2026

Introduction Dengue continues to emerge as a major global public health challenge, driven by rapid urbanisation, climate change, and the expansion of mosquito habitats. Conventional vector-control strategies such as insecticides, source reduction, and repellents have shown limited and often unsustained impact, while vaccine options remain suboptimal across all serotypes. This has led to growing interest in biologically innovative approaches. One such strategy involves infecting male Aedes aegypti mosquitoes with Wolbachia bacteria, which induces cytoplasmic incompatibility and prevents viable offspring when these males mate with wild-type females, thereby suppressing mosquito populations and potentially reducing dengue transmission. Problem Statement Despite multiple preventive strategies, dengue incidence continues to rise globally, highlighting a critical gap in effective, scalable, and sustainable vector-control interventions. While Wolbachia-based methods have shown promise in observational and limited trials, robust randomised evidence demonstrating real-world epidemiologic benefit—particularly using male-only sterile mosquito release (IIT-SIT approach)—has been lacking. Summary This large cluster-randomised trial in Singapore demonstrated that releasing Wolbachia-infected male mosquitoes significantly reduced both mosquito density and dengue incidence. Female mosquito abundance dropped markedly in intervention areas, and dengue positivity rates decreased from 21% in control clusters to 6% in intervention clusters. The intervention achieved a protective efficacy of approximately 71–72% after sustained exposure. These findings provide strong real-world evidence that Wolbachia-based vector suppression is an effective, environmentally sustainable strategy for dengue control. This approach represents a major shift from chemical-based control toward biological population suppression, with potential scalability in urban settings worldwide.